Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

摘要

We read with interest the study by Koh et al.,which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrag-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) (Table 1).The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients. We recently presented the results of a comprehensive, multicentre TBNET (TuBerculosis Network European Trials Group) evaluation of linezolid tolerability and long-term efficacy for the treatment of MDR- and XDR-TB.